



With respect to risks associated with research involving human subjects, all contracts, protocols or investigator agreements for industrial sponsorship of clinical trials or for participation in such clinical trials shall be deemed to provide that the clinical investigators shall not be prevented by the sponsor or anyone else from informing participants in the study, members of the research group, other physicians administering the treatment, research ethics boards, regulatory agencies and the scientific community, of risks to participants that the investigators identify during the research. These provisions also apply to any risks from a treatment so identified following the conclusion of a trial if there are patients being administered the treatment in a non-trial setting. The term "risk" includes but is not limited to the inefficacy of the treatment and direct safety concerns.

All contracts, protocols or investigator agreements for industrial sponsorship of clinical trials or for participation in such clinical trials shall reproduce this declaration on Integrity of Research and the declaration on Academic Freedom

<b>Version</b>	<b>Date</b>	<b>Authors/Comments</b>
1.0	2003 12 02	Approved by the Board of Directors as Appendix G within By-Law No 2 (consolidated version Dec 2, 2003 including By-Law amendments passed on September 27, 2006)
2.0	2013 11 29	No revisions – Stand-alone policy approved by the Board of Directors pursuant to the Governance Review of 2012-2013 in the Board Policy Manual.
2.1	2019 02 20	No revisions – Updated to new Template pursuant to request of COO